Anzeige
Erschienen in:
01.04.2003 | Editorial
Xerostomia—any progress?
Erschienen in: Supportive Care in Cancer | Ausgabe 4/2003
Einloggen, um Zugang zu erhaltenExcerpt
The articles by Jensen et al. and Nieuw Amerongen et al. collectively address the pathophysiology and management of cancer therapy-mediated salivary gland injury and its sequelae. There has been considerable research of salivary disease in non-cancer patients, including those with Sjögren's syndrome. The current two articles summarize salivary research in cancer patients, and lead one to the following conclusions:-
The symptom of xerostomia (oral dryness) does not necessarily correlate with the signs of salivary gland hypofunction.
-
The oral cavity represents a unique anatomic and functional complex, including salivary defense mechanisms and colonizing microflora.
-
This unique complex, including salivary tissue, is at varying degrees of risk of injury secondary to cancer treatment.
-
The molecular model of salivary injury is currently more well defined in head and neck radiation patients than in chemotherapy patients. However, more research in both domains is needed in order to strategically advance management of these patients.
-
Salivary hypofunction increases the risk for multiple complications including mucositis, dysgeusia and oral and systemic infection.